Lung Cancer Diagnosis

Lung Cancer and Early Detection

Why we are tackling lung cancer first

While Micronoma’s approach indicates very strong performances across multiple cancers, including at the earliest stages (I and II)*, we are initially focused on developing an LDT for diagnosing lung cancer, since it is among the most common and the deadliest.

*Poore, G. D. et. al. (2020). Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature.

The American Cancer Society estimates that lung cancer will account for about 18% of cancer deaths worldwide and 25% of all cancer deaths in the U.S. (about 130,180 deaths in 2022).

Lung Cancer in the U.S.

Only breast cancer is more common for women, while only prostate cancer is more common for men (not counting skin cancer for both).

13% of All
Cancer Cases

25% of All
Cancer Deaths

One of the deadliest forms of cancer,

but it doesn’t have to be…

When lung cancer is caught early enough to be localized, survival rates can improve dramatically.

Extrapolated from: Morgan, K. K.  (2021, September 1). WebMD. Your Chances of Surviving Lung Cancer. Retrieved from

The survival rate for patients whose lung cancer is detected in stage I is as high as 82 percent –
a 16-fold increase over patients detected in stage IV.1

  At risk population is relatively well defined, but underserved

Micronoma’s OncobiotaLUNGdetect has the potential to provide early diagnosis to populations with a relatively well-defined risk profile compared to other cancers, namely the approximately 1.5 million people in the U.S. ages 50-plus who have smoked a pack or more of cigarettes per day for 20 years or more.2

That at-risk population must currently rely on low-dose CT (LDCT) scans for screening. While the scans are covered by Medicare, only about 5% of those eligible are going through the process. One reason is the lack of access to testing centers, especially in rural areas.3 But this is not the only reason.

Current methods post LDCT can be risky and costly

At least 96.4% of LDCT scans which reveal a lung nodule are later determined as benign. While good news for those patients, LDCT scans require tissue biopsies, which are costly. In addition, the procedure carries some serious risk, with about 20% of those tested experiencing side effects (lung infections, pneumothorax, etc.). Another procedure to determine if nodules are malignant is a PET CT scan. While this may be a little less costly than tissue biopsy, it relies on the injection of significant doses of radioactivity and lacks sensitivity in stage I of the disease (as low as 38%).4

More modern liquid biopsy technologies that test circulating tumor DNA (ctDNA) and proteins, and/or DNA methylation are available. But they often offer poor sensitivity or do not provide strong early-stage detection. 5

Oncobiota Platform


In the event of a positive LDCT scan, using a simple blood draw and OncobiotaLUNGdetect  provides another diagnostic option for clinicians and their patients, and could make it possible for patients to avoid more expensive and more invasive tissue biopsies by determining the likelihood of a lung nodule to be malignant via blood samples, even for nodules discovered in stage I of the disease.

Improving early cancer detections can ultimately save costs, time, and, most importantly, lives.

1. American Cancer Society (2019, October 1). Lung Cancer Survival Rates. Retrieved from

2. Jonas DE, Reuland DS, Reddy SM, et al. Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021;325(10):971–987. doi:10.1001/jama.2021.0377

3. Fedewa, S. A. et. al (2021). State Variation in Low-Dose Computed Tomography Scanning for Lung Cancer Screening in the United States. Journal of the National Cancer Institute, 113(8), 1044–1052.

4. Chiu, Y. W. et. al. (2021). Costs of Biopsy and Complications in Patients with Lung Cancer. ClinicoEconomics and outcomes research : CEOR, 13, 191–200.

5. Adams, E., Sepich-Poore, G. D., Miller-Montgomery, S., Knight, R.. VIEW. 2022, 3, 20200118.

For more info, see:

Website Terms of Use, Privacy Policy, and Licenses and Accreditations

Micronoma, INC., CLIA #05D2253538

Oncobiota™ LDT is under development and is currently not available for commercial use in any jurisdiction. Once available under CLIA license, Oncobiota™ will be available in the United States by prescription only.

Contact Us

If you have questions or would like to learn more, please email us at or learn about joining our team at Careers.

6342 Ferris Square
San Diego, CA 92121